News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Mar 22, 2005

OSI Pharmaceuticals Announces Tarceva Granted First European Approval in Switzerland; First and Only Agent Approved in its Class to Show a Survival Benefit
Mar 16, 2005

Mycamine™ Receives FDA Approval

Fujisawa Healthcare, Inc.'s Echinocandin to Fight Candida Fungal Infections
Jan 27, 2005

Data from Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients

Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer

Show per page